HCP Resources

Patient Resources

Solstice Neurosciences, Inc. is committed to providing you with the most up-to-date resources to help you and your patients with cervical dystonia.

Information Request:
If you have questions about MYOBLOC, need information, or would like an Area Account Manager to visit your practice, please call 1-888-461-2255.

Listed below are titles of clinical studies of MYOBLOC

Titles of Some Clinical Studies
Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53(7):1439-1446.

Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53(7):1431-1438.

Comella CL, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. 2005. Neurology. 65:9;1423-1429.

Factor SA, Molho E et al. Efficacy and Safety of Repeated Doses of Botulinum Toxin Type B in Type A-Resistant and Responsive Cervical Dystonia. 2005. Movement Disorders. 20:9;1152-1160.

Lew MF. Botulinum toxin type B: an effective treatment for alleviating pain associated with cervical dystonia. J Back Musculoskeletal Rehabil. 2002;16:3-9.

Pappert EJ, Germanson T; The Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord. 2008;23(4):510-517.

If you have other questions about the clinical use of MYOBLOC, call 1-888-461-2255, or click here to download a Medical Information Request form that you can fax to us.

Sales Call Request
Request a visit from an Area Account Manager by calling 1-888-461-2255 Monday through Friday from 8 AM to 7 PM Eastern Time, or by contacting your Solstice Neurosciences, Inc. sales representative.

To order MYOBLOC, obtain information about reimbursement, or for general information, call 1-888-461-2255.

See Important Safety Information below.

An online professional educational program for HCPs who diagnose and treat neck pain associated with cervical dystonia.

Important Safety Information

Myobloc^® (Botulinum Toxin Type B) Injectable Solution is indicated for the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.

Before administering MYOBLOC, physicians should consult the full Prescribing Information.

The most frequently reported adverse events with MYOBLOC are dry mouth, dysphagia, dyspepsia, and injection site pain. These adverse events are generally mild to moderate, transient, self-resolving, and more common with higher doses. Dysphagia is commonly reported with all botulinum toxins in cervical dystonia patients.

Caution should be exercised when administering MYOBLOC to individuals with motor neuron disease (eg, amyotrophic lateral sclerosis), peripheral motor neuropathic diseases (eg, motor neuropathy) or neuromuscular junctional disorders (eg, myasthenia gravis or Lambert-Eaton syndrome). These patients may be at increased risk of clinically significant systemic effects including severe dysphagia and respiratory compromise from typical doses of MYOBLOC. In these patients, rare cases of dysphagia severe enough to cause aspiration pneumonia or to warrant the insertion of a gastric feeding tube have also been reported.

Coadministration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.

Click here for Important Safety Information and full Prescribing Information

Myobloc University | Important Safety Information | Prescribing Information
Terms of Use | Privacy Policy | References